ASH 2020 | Promising BCMA-targeting CAR-T cells for relapsed myeloma
Elisabet Manasanch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I first-in-human trial (NCT03602612) of FHVH-BCMA-T, a BCMA-targeting CAR T-cell therapy with a novel heavy chain only antigen recognition domain for the treatment of relapsed multiple myeloma. FHVH-BCMA-T was designed to reduce the risk of host immune responses against the CAR T-cells. The trial evaluated efficacy and tolerability of the treatment at dose levels, establishing 6 x 10^6 CAR+ T cells/kg as the maximum feasible dose. The results showed deep and durable responses, as well as a promising safety profile. The substantial overall response rate seen in this difficult to treat population supports FHVH-BCMA-T use, and enrollment into an expansion cohort has begun. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
